The Online Books Page

Drug Approval

See also what's at your library, or elsewhere.

• Pharmaceutical policy

• Drug Approval -- United States
• Drug approval -- Corrupt practices

• Approval of drugs
• Approval of new drugs
• Drug approval process
• New drug approval

• FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session part 1 (U.S. G.P.O. :, 1989), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Review time has decreased in recent years (The Office ;, 1995), by United States General Accounting Office (page images at HathiTrust)
• The impact of medical device and drug regulation on innovation, jobs, and patients : a local perspective : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, first session, September 26, 2011. (U.S. G.P.O. :, 2012), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)

• Guideline for submitting documentation for packaging for human drugs and biologics (U. S. Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline for the format and content of the summary for new drug and antibiotic applications. (Center for Drugs and Biologics, Food and Drug Administration, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline for the format and content of the human pharmacokinetics and bioavailability section of an application. (Center for Drugs and Biologics, Food and Drug Administration, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline on formatting, assembling, and submitting new drug and antibiotic applications. (Center for Drugs and Biologics, Food and Drug Administration, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline for the format and content of the chemistry, manufacturing, and controls section of an application. (Center for Drugs and Biologics, Food and Drug Administration, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline for submitting supporting documentation in drug applications for the manufacture of drug substances (U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline for submitting samples and analytical data for methods validation. (Food and Drug Administration, Center for Drugs and Biologics, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline for submitting documentation for the manufacture of and controls for drug products. (Center for Drugs and Biologics, Food and Drug Administration, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session part 1 (U.S. G.P.O. :, 1989), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• RU 486 (U.S. G.P.O. :, 2007), by Drug Policy United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice (page images at HathiTrust)
• Ketek clinical study fraud : what did Aventis know? : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, February 12, 2008. (U.S. G.P.O. :, 2008), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Committee prints on administration legislative proposals on the Animal Drug User Fee Act Amendments of 2008 and the Animal Generic Drug User Fee Act of 2008 : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, June 5, 2008. (U.S. G.P.O. :, 2008), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• Council on Competitiveness and FDA plans to alter the drug approval process at FDA : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, second session, March 19, 1992. (U.S. G.P.O. :, 1993), by United States. Congress. House. Committee on Government Operations. Human Resources and Intergovernmental Relations Subcommittee (page images at HathiTrust)
• PDUFA 5 (U.S. G.P.O. :, 2012), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• The impact of medical device and drug regulation on innovation, jobs, and patients : a local perspective : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, first session, September 26, 2011. (U.S. G.P.O. :, 2012), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012. (Washington : U.S. Government Printing Office, 2013., 2013), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• FDA user fees 2012 : how innovation helps patients and jobs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, April 18, 2012. (Washington : U.S. Government Printing Office, 2013., 2013), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• FDA user fees 2012 : issues related to accelerated approval, medical gas, antibiotic development, and downstream pharmaceutical supply chain : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, March 8, 2012. (Washington : U.S. Government Printing Office, 2013., 2013), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)

• Report to the nation (U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1997), by Center for Drug Evaluation and Research (U.S.) (page images at HathiTrust)

• Report to the nation (U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1997), by Center for Drug Evaluation and Research (U.S.) (page images at HathiTrust)

• Staff report on Sanofi's strategic use of third parties to influence the FDA (U.S. G.P.O. :, 2011), by United States. Congress. Senate. Committee on Finance (page images at HathiTrust)

Items below (if any) are from related and broader terms.

• Intellectual Property and Public Health in the Developing World (Cambridge, UK: Open Book Publishers, c2016), by Mohammad Monirul Azam (multiple formats with commentary at Open Book Publishers)
• FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session part 1 (U.S. G.P.O. :, 1989), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Pharmacist's manual : an informational outline of the Controlled substances act of 1970. (Drug Enforcement Administration, U.S. Department of Justice, 1980), by United States. Drug Enforcement Administration. Office of Compliance and Regulatory Affairs (page images at HathiTrust)
• Granting additional market exclusivity to the drug Ansaid : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, February 20, 1992. (U.S. G.P.O. :, 1992), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• Drug manual for pharmacies. (State of Illinois, Dept. of Public Aid, 1964), by Illinois. Department of Public Aid (page images at HathiTrust)

• Drug manual for pharmacies. (State of Illinois, Dept. of Public Aid, 1964), by Illinois. Department of Public Aid (page images at HathiTrust)

• Report of the Select Joint Committee on Generic Drug Substitution. (Legislative Services Agency, Legislative Council, 1978), by Select Joint Committee on Generic Drug Substitution, Indiana. General Assembly. Legislative Services Agency, and Indiana. General Assembly. Legislative Council (page images at HathiTrust)

• Premarket approval (PMA) manual (HHS, 1986), by United States Food and Drug Administration (page images at HathiTrust)

• Journal of Pharmaceutical Policy and Practice (2014-) (partial serial archives)

• Prices, Markets, and the Pharmaceutical Revolution (Washington: AEI Press, 2000), by John E. Calfee (PDF at AEI)
• Prescription for the People: An Activist's Guide to Making Medicine Affordable for All (Ithaca, NY and London: ILR Press, c2017), by Fran Quigley (PDF and Epub with commentary at Cornell Open)
• Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease (Washington: Office of Technology Assessment, 1992), by Alan M. Garber, Ann E. Clarke, Dana P. Goldman, and Michael E. Gluck (PDF files at Princeton)
• Final report (Dept. of Health, Education, and Welfare, 1977), by Education United States. Department of Health (page images at HathiTrust)
• Assuring pharmacy services : principles and guidelines for the delivery of mandated pharmacy services in BCHS primary care projects. (U.S. Dept. of Health, Education, and Welfare, Public Health Service, Health Services Administration, Bureau of Community Health Services (5600 Fishers Lane), 1980), by United States. Health Services Administration. Bureau of Community Health Services (page images at HathiTrust)
• Update of federal activities regarding the use of pneumococcal vaccine. (Congress of the United States, Office of Technology Assessment :, 1984), by United States Congress Office of Technology Assessment (page images at HathiTrust)
• Final report of the Advisory Committee on the Food and Drug Administration. (The Committee, 1991), by United States. Dept. of Health and Human Services. Advisory Committee on the Food and Drug Administration (page images at HathiTrust)
• Report of the National Commission on Orphan Diseases. (U.S. Dept. of Health & Human Sevices, Public Health Service, Office of the Assistant Secretary for Health, 1989), by National Commission on Orphan Diseases (U.S.) (page images at HathiTrust)
• Drug regulation reform--oversight hearing before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, second session .... (U.S. G.P.O., 1980), by United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• Pharmaceutical innovation--promises and problems hearing before the Subcommittee on Natural Resources, Agriculture Research, and Environment and the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives, Ninety-seventh Congress, first session, April 27, 1981. (U.S. G.P.O., 1982), by Agriculture Research United States. Congress. House. Committee on Science and Technology. Subcommittee on Natural Resources and United States. Congress. House. Committee on Science and Technology. Subcommittee on Investigations and Oversight (page images at HathiTrust)
• Drug lag hearing before the Subcommittee on Natural Resources, Agriculture Research, and Environment of the Committee on Science and Technology, U.S. House of Representatives, Ninety-seventh Congress, first session, September 16, 1981. (U.S. G.P.O., 1983), by Agriculture Research United States. Congress. House. Committee on Science and Technology. Subcommittee on Natural Resources (page images at HathiTrust)
• Uncertain returns : the multimillion dollar market in reimported pharmaceuticals : a staff report (U.S. G.P.O. :, 1986), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session part 1 (U.S. G.P.O. :, 1989), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• The Food and Drug Administration's process for approving new drugs oversight : hearings before the Subcommittee on Science, Research, and Technology of the Committee on Science and Technology, U.S. House of Representatives, Ninety-sixth Congress, first session, June 19, 21, July 11, 1979. (U.S. Govt. Print. Off., 1979), by Research United States. Congress. House. Committee on Science and Technology. Subcommittee on Science (page images at HathiTrust)
• The Food and Drug Administration's process for approving new drugs : report (U.S. G.P.O. :, 1980), by Research United States. Congress. House. Committee on Science and Technology. Subcommittee on Science (page images at HathiTrust)
• New drug development in the United States (Dept. of Health & Human Services, Public Health Service, Food and Drug Administration, 1995), by United States Food and Drug Administration (page images at HathiTrust)
• Pill mills, Medicaid fraud, and the diversion of pharmaceuticals : hearing before the Select Committee on Narcotics Abuse and Control, House of Representatives, One Hundred Second Congress, second session, July 29, 1992. (U.S. G.P.O. :, 1992), by United States. Congress. House. Select Committee on Narcotics Abuse and Control (page images at HathiTrust)
• RU-486, status report on the U.S. commercialization project, transfer of antiprogestin technology to the United States : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, second session, Washington, DC, May 16, 1994. (U.S. G.P.O. :, 1994), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• The federal government's investment in new drug research and development : are we getting our money's worth? : hearing before the Special Committee on Aging, United States Senate, One Hundred Third Congress, first session, Washington, DC, February 24, 1993. (U.S. G.P.O. :, 1993), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Advisory Committee on the Food and Drug Administration : final report : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Second Congress, first session, on reviewing the Advisory Committee on the Food and Drug Administration report on the current state of FDA, and its recommendations to strengthen FDA, May 15, 1991. (U.S. G.P.O. :, 1992), by United States Senate Committee on Labor and Human Resources (page images at HathiTrust)
• Department of Veterans Affairs pharmacy program with emphasis on OTC drugs, medical supplies, and dietary supplements : hearing before the Subcommittee on Hospitals and Health Care of the Committee on Veterans' Affairs, House of Representatives, One Hundred Fourth Congress, second session, June 11, 1996. (U.S. G.P.O. :, 1996), by United States. Congress. House. Committee on Veterans' Affairs. Subcommittee on Hospitals and Health Care (page images at HathiTrust)
• The effect of federal ban of RU 486 on medical research, new drug development, and pharmaceutical manufacturers : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, second session, Washington, DC, July 28, 1992. (U.S. G.P.O. :, 1993), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• FDA review and approval times : statement of Mary R. Hamilton, Director of Program Evaluation in the Human Services Area, Program Evaluation and Methodology Division, before the Committee on Labor and Human Resources, U.S. Senate / United States General Accounting Office. (The Office ;, 1996), by United States General Accounting Office, Mary R. Hamilton, and United States Senate Committee on Labor and Human Resources (page images at HathiTrust)
• Oversight hearing on the availability and eligibility for pharmaceutical services provided by the Department of Veterans Affairs : hearing before the Subcommittee on Health of the Committee on Veterans' Affairs, House of Representatives, One Hundred Eight [sic] Congress, first session, March 19, 2003. (U.S. G.P.O. :, 2004), by United States. Congress. House. Committee on Veterans' Affairs. Subcommittee on Health (page images at HathiTrust)
• Greater Access to Affordable Pharmaceuticals Act (U.S. G.P.O. :, 2004), by United States Senate Committee on the Judiciary (page images at HathiTrust)
• Pharmacist's manual : an informational outline of the Controlled substances act of 1970. (Drug Enforcement Administration, U.S. Department of Justice, 1980), by United States. Drug Enforcement Administration. Office of Compliance and Regulatory Affairs (page images at HathiTrust)
• Importation of prescription drugs : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eighth Congress, second session, on examining prescription drug reimportation, focusing on efforts to reduce drug costs, patient safety concerns, recent state action, fraudulent and counterfeit drugs, an international comparison of rising prescription drug expenditures, and S. 2328, to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, May 20, 2004. (U.S. G.P.O. :, 2005), by United States Senate Committee on Health, Education, Labor, and Pensions (page images at HathiTrust)
• Food and Drug Administration's drug approval process (U.S. G.P.O. :, 2005), by United States Senate Committee on Health, Education, Labor, and Pensions (page images at HathiTrust)
• Realities of safety and security regarding drug importation (U.S. G.P.O. :, 2005), by United States Senate Committee on Health, Education, Labor, and Pensions (page images at HathiTrust)
• Drug importation : would the price be right? : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, first session, on examining the price of drug reimportation, focusing on implications for United States consumers, pricing, research and development, and innovation, February 17, 2005. (U.S. G.P.O. :, 2005), by United States Senate Committee on Health, Education, Labor, and Pensions (page images at HathiTrust)
• Oxycontin and beyond : examining the role of FDA and DEA in regulating prescription painkillers : hearing before the Subcommittee on Regulatory Affairs of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, first session, September 13, 2005. (U.S. G.P.O. :, 2005), by United States. Congress. House. Committee on Government Reform. Subcommittee on Regulatory Affairs (page images at HathiTrust)
• The adequacy of FDA to assure the safety of the nation's drug supply : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, February 13, March 22, 2007. (U.S. G.P.O. :, 2007), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Prescription drug abuse : what is being done to address this new drug epidemic? : hearing before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, second session, July 26, 2006. (U.S. G.P.O. :, 2007), by Drug Policy United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice (page images at HathiTrust)
• Examining the implications of drug importation : hearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, second session, July 14, 2004. (U.S. G.P.O. :, 2008), by United States Senate Committee on the Judiciary (page images at HathiTrust)
• From test tube to patient : new drug development in the United States. (Dept. of Health & Human Services, Public Health Service, Food and Drug Administration, 1990), by United States Food and Drug Administration (page images at HathiTrust)
• The federal government's investment in new drug research and development : are we getting our money's worth? : hearing before the Special Committee on Aging, United States Senate, One Hundred Third Congress, first session, Washington, DC, February 24, 1992. (U.S. G.P.O. :, 1993), by United States Senate Special Committee on Aging (page images at HathiTrust)
• FDA's generic drug application policy : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, second session, July 28, 1988. (U.S. G.P.O. :, 1989), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Granting additional market exclusivity to the drug Ansaid : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, February 20, 1992. (U.S. G.P.O. :, 1992), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• The war on drugs meets the war on pain : nursing home patients caught in the crossfire : listening session before the Special Committee on Aging, United States Senate, One Hundred Eleventh Congress, second session, Washington, DC, March 24, 2010. (U.S. G.P.O. :, 2010), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Legislative proposal to increase funding for medical research : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Fifth Congress, first session, special hearing. (U.S. G.P.O. :, 1998), by Health and Human Services United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor (page images at HathiTrust)
• Council on Competitiveness and FDA plans to alter the drug approval process at FDA : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, second session, March 19, 1992. (U.S. G.P.O. :, 1993), by United States. Congress. House. Committee on Government Operations. Human Resources and Intergovernmental Relations Subcommittee (page images at HathiTrust)
• What is the US role in combating the global HIV/AIDS epidemic? (U.S. G.P.O. :, 2000), by Drug Policy United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice (page images at HathiTrust)
• Department of Veterans Affairs pharmaceutical procurement polcy : hearing before the Subcommittee on Health of the Committee on Veterans' Affairs, House of Representatives, One Hundred Sixth Congress, second session, July 25, 2000. (U.S. G.P.O. :, 2001), by United States. Congress. House. Committee on Veterans' Affairs. Subcommittee on Health (page images at HathiTrust)
• Examining prescription drug importation : a review of a proposal to allow third parties to reimport prescription drugs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, July 25, 2002. (U.S. G.P.O. :, 2002), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• Evaluating the effectiveness of the Food And Drug Administration Modernization Act : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, May 3, 2001. (U.S. G.P.O. :, 2001), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• Policy implications of pharmaceutical importation for U.S. consumers : hearing before the Subcommittee on Interstate Commerce, Trade, and Tourism of the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Tenth Congress, first session, March 7, 2007. (U.S. G.P.O. :, 2013), by Science United States. Congress. Senate. Committee on Commerce (page images at HathiTrust)
• Drug safety : an update from the Food and Drug Administration : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, second session, March 10, 2010. (Washington, DC : For sale by the Superintendent of Documents, U.S. Government Printing Office., 2012), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• Prescription drug price inflation : are prices rising too fast? : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, first session, December 8, 2009. (U.S. G.P.O. :, 2012), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• Preliminary report of the survey on drugs for rare disease (U.S. G.P.O., 1982), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• Committee report on scheduling of controlled substances, precursors, chemicals and controlled substances analogs : presented at the National Conference on the Control and Diversion of Controlled Substances, San Antonio, Texas, 1987. (U.S. Dept. of Justice, Drug Enforcement Administration, 1988), by Tex.) National Conference on the Control and Diversion of Controlled Substances (3rd : 1987 : San Antonio and United States. Drug Enforcement Administration (page images at HathiTrust)
• Committee report on license revocation & management control systems : presented at the National Conference on the Control and Diversion of Controlled Substances,San Antonio, Texas, 1987. (U.S. Dept. of Justice, Drug Enforcement Administration, 1988), by Tex.) National Conference on the Control and Diversion of Controlled Substances (3rd : 1987 : San Antonio and United States. Drug Enforcement Administration (page images at HathiTrust)
• An introduction to FDA drug regulation : a manual for pharmacists. (Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research and Office of Regulatory Affairs, 1990), by Center for Drug Evaluation and Research (U.S.) (page images at HathiTrust)
• Commission on the Federal Drug Approval Process : final report (U.S. G.P.O., 1982), by United States. Commission on the Federal Drug Approval Process, United States. Congress. House. Committee on Science and Technology. Subcommittee on Investigations and Oversight, and Agriculture Research United States. Congress. House. Committee on Science and Technology. Subcommittee on Natural Resources (page images at HathiTrust)
• Examining drug shortages and recent efforts to address them : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, February 10, 2014. (Washington : U.S. Government Printing Office, 2014., 2014), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)

More items available under broader and related terms at left.